Joe Y Chang, Endowed Texas 4000 Distinguished Professor and Director of Stereotactic Ablative Radiotherapy Program at MD Anderson Cancer Center, shared a post on X by Alejandro Bribriesco, Staff Surgeon and Assistant Professor of Surgery at Louis Stokes Cleveland VAMC, adding:
“455/670 patients have been enrolled in a phase III randomized study comparing SABR vs surgery in early-stage NSCLC with 2.5 Y median F/U. Complete enrollment is anticipated in 2027.
I still remember I participated NCI advisory committee meeting and fought for VALOR in 2015.”
Quoting Alejandro Bribriesco’s post, shared from Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and CMO of Respirati:
“Update on status of VALOR (CSP2005) – RCT of Surgery vs SBRT for early stage Lung Cancer in surgical candidates in the U.S. Department of Veterans Affairs.”
Quoting Drew Moghanaki’s post:
“That’s David Harpole at WCLC25, pointing out that with 70% already accrued to the VALOR study, more than 120 participants have already completed their 5-year follow-up period.
Insert David’s finger in the bottom right figure.”
More posts featuring Joe Y Chang.